In-Person And Virtual Options To Get Unleashed In The Immunoassay Interference Blocker Market, Reaching US$ 455 Mn

The global Immunoassay Interference Blocker Market is all set to witness a CAGR of 6.7% in the next decade. It is expected to reach US$ 455 Mn by the year 2031. With digitized communication channels making a beeline to the healthcare vertical, the advanced clinics are into virtual consultation mode, and this scenario is expected to continue even going forward. Regulatory approvals for this type of communication are on the way. Close to 70% of the public hospitals worldwide are being asked to adopt digital means. This would be the scene with healthcare vertical in the subsequent period.

As per Persistence Market Research's latest revised industry analysis, the global immunoassay interference blocker market was valued at US$ 223 Mn in 2020, and is expected to exhibit a CAGR of 6.7% over the forecast period (2021-2031).

Substances that modify quantifiable concentration of analytes or change antibody binding can conceivably result in immunoassay interference. Prevalence of interference is usually less in assays holding blocking agents, which counteract or inhibit the interference. Detection of interference may involve usage of a different assay, or quantification before and after treatment with supplementary blocking reagents.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/24343

Growing prevalence of chronic diseases and increasing aging population across the world are factors that are expected to surge the need for biochemical testing for the management of chronic diseases. Increase in aging population is likely to escalate demand for diagnostic kits and reagents for the detection of age-related as well as other chronic conditions. This is expected to drive the immunoassay interference blocker market over the forecast period of 2021 to 2031.

Governments around the world are supporting the growth of specialty medical diagnostic reagents, which further drives research & development. Immunoassay interference blocker kits and reagents play a vital role in preventing unnecessary interference generated while preforming an immunoassay-based disease detection test. Hence, an increase in growth of immunoassay interference blockers has been witnessed due to rising government support and funding.

Key manufacturers of immunoassay interference blockers have been focusing on expansion and new product launch programs to increase their consumer base in different geographies.

In 2019, Bio Rab Laboratories announced the launch of an innovative test to aid in the diagnosis of Lyme disease, with the FDA clearance of the bioplex 2200 Lyme total assay.

In 2021, Thermofisher Scientific planned for its manufacturing site expansion in the region of Mebane, N.C. USA.

Company Profiles:

Abcam plc
AMS BioApplication (Europe) Limited
Aviva Systems Biology Corporation
Bio-Rad Laboratories, Inc.
Meridian Bioscience, Inc.
Roche Diagnostics GmbH
Rockland Immunochemicals, Inc.
Scantibodies Laboratory, Inc.
Thermo Fisher Scientific

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/24343

Key Takeaways from Market Study

Antibody interference blockers hold the largest market share as compared to other products, expanding at a CAGR of 6.4%. A similar trend is expected to continue, primarily due to their high efficiency and reliable assay outcomes.

The application segment is led by antibody capture assays with a share of 39.8% in 2020, owing to high, precise, and accurate results with least interference obtained via immunoassay interference blockers.

Academic and research institutes dominated the end user segment with a share of around 39.5% in 2020. This segment is expected to grow two-fold by the end of 2031 due to increasing usage of immunoassay interference blockers in research activities to introduce novel applications.

By region, North America is slated to be the largest regional market with a value share of 33.3% at the end of the forecast period, due to constant clinical efforts to establish advanced diagnostics biologics and new drug discovery in the region.

"Increasing healthcare R&D spending and government support, continual technological advancements, and growing demand for better diagnosis are boosting demand for immunoassay interference blockers," says an analyst of Persistence Market Research.

Impact of Market Consolidation

Considering consolidation activities in the global market, strategic focus on novel product development and research based on advanced immunoassay interference blockers are some of the key growth strategies by market players. Prominent players are strengthening their product ranges through acquisitions and reaching out to key as well as emerging markets.

For instance:

In April 2020, Bio Rad Laboratories, Inc. announced the commercial launch of its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/24343

Market Landscape

The exhaustive research report on global immunoassay interference blocker market has detailed analysis on the various key players involved in this market.

Key companies such as Abcam plc, AMS Biotechnology (Europe) Limited, Aviva Systems Biology Corporation, Bio-Rad Laboratories, Inc., Meridian Bioscience, Inc., Roche Diagnostics GmbH, Rockland Immunochemicals, Inc., Scantibodies Laboratory, Inc. and Thermo Fisher Scientific are profiled in this research study.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the immunoassay interference blocker market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.

Access Related Reports-

Urothelial Carcinoma Diagnostics Market: https://www.persistencemarketresearch.com/market-research/urothelial-carcinoma-diagnostics-market.asp

Gastrointestinal Infection Testing Market: https://www.persistencemarketresearch.com/market-research/gastrointestinal-infection-testing-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.